Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

MLA

Kantarjian, Hagop M., et al. “Bosutinib Safety and Management of Toxicity in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors.” Blood, vol. 123, no. 9, Feb. 2014, pp. 1309–18. EBSCOhost, https://doi.org/10.1182/blood-2013-07-513937.

APA

Kantarjian, H. M., Cortes, J. E., Kim, D.-W., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E., Kelly, V., Turnbull, K., Besson, N., & Gambacorti-Passerini, C. (2014). Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 123(9), 1309–1318. https://doi.org/10.1182/blood-2013-07-513937

Chicago

Kantarjian, Hagop M., Jorge E. Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H. Brümmendorf, Kimmo Porkka, Giovanni Martinelli, et al. 2014. “Bosutinib Safety and Management of Toxicity in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors.” Blood 123 (9): 1309–18. doi:10.1182/blood-2013-07-513937.